PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Phase:
PHASE2
Details
Lead Sponsor:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators:
FHI Clinical, Inc. Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies RedHill Biopharma Limited